CASSADER, Maurizio
 Distribuzione geografica
Continente #
NA - Nord America 13616
EU - Europa 10160
AS - Asia 6005
SA - Sud America 301
OC - Oceania 139
AF - Africa 95
Continente sconosciuto - Info sul continente non disponibili 24
Totale 30340
Nazione #
US - Stati Uniti d'America 13035
CN - Cina 3978
IT - Italia 1554
IE - Irlanda 1452
SE - Svezia 1365
FR - Francia 976
UA - Ucraina 884
DE - Germania 818
FI - Finlandia 639
KR - Corea 610
GB - Regno Unito 499
AT - Austria 428
CA - Canada 389
JP - Giappone 385
PL - Polonia 372
DK - Danimarca 345
VN - Vietnam 314
ES - Italia 176
MX - Messico 164
IN - India 142
RU - Federazione Russa 128
BR - Brasile 126
AU - Australia 123
TW - Taiwan 115
BE - Belgio 108
TR - Turchia 85
GR - Grecia 80
NL - Olanda 76
HK - Hong Kong 57
RO - Romania 53
TH - Thailandia 49
IR - Iran 45
PT - Portogallo 40
CL - Cile 39
PE - Perù 39
PH - Filippine 39
CO - Colombia 38
ID - Indonesia 38
SG - Singapore 33
AR - Argentina 32
CH - Svizzera 27
EG - Egitto 25
SN - Senegal 25
EU - Europa 24
SI - Slovenia 23
BY - Bielorussia 22
CZ - Repubblica Ceca 22
IL - Israele 21
MY - Malesia 21
EC - Ecuador 19
NO - Norvegia 17
SA - Arabia Saudita 16
HU - Ungheria 13
NZ - Nuova Zelanda 12
PK - Pakistan 11
LU - Lussemburgo 10
BG - Bulgaria 9
TN - Tunisia 9
MU - Mauritius 8
GT - Guatemala 7
IQ - Iraq 7
KZ - Kazakistan 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
AN - Antille olandesi 5
CR - Costa Rica 5
CV - Capo Verde 5
HR - Croazia 5
LB - Libano 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
DZ - Algeria 4
KE - Kenya 4
QA - Qatar 4
VE - Venezuela 4
BD - Bangladesh 3
JM - Giamaica 3
PG - Papua Nuova Guinea 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
AL - Albania 2
GH - Ghana 2
IS - Islanda 2
JO - Giordania 2
LT - Lituania 2
LV - Lettonia 2
MK - Macedonia 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
PS - Palestinian Territory 2
SC - Seychelles 2
BA - Bosnia-Erzegovina 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
HN - Honduras 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
Totale 30331
Città #
Beijing 1898
Chandler 1737
Dublin 1438
Ann Arbor 1235
Fairfield 818
Houston 772
Jacksonville 689
Villeurbanne 627
Wilmington 604
Princeton 577
Woodbridge 559
Redwood City 484
Medford 465
Vienna 413
Dearborn 410
Nyköping 382
Torino 372
Ashburn 359
Seattle 326
Warsaw 318
Cambridge 289
Pisa 288
Shanghai 251
Dong Ket 223
Boston 210
Guangzhou 174
Hangzhou 159
Nanjing 156
Boardman 155
Ottawa 155
Fremont 123
Norwalk 94
Milan 93
Wuhan 88
Taipei 85
Tokyo 83
Toronto 76
Chengdu 74
Hefei 65
Brussels 60
Chongqing 56
Jinan 56
Verona 56
San Diego 54
Shenyang 54
Phoenix 48
Kunming 47
Falls Church 46
Menlo Park 45
Tianjin 44
Xian 43
Central District 41
Changsha 39
Seoul 39
Rome 36
San Mateo 36
Zhengzhou 36
Changchun 34
Munich 30
Duncan 29
London 29
Silver Spring 29
Düsseldorf 28
Mexico 28
Mountain View 28
Nanchang 28
Saint-hubert 28
Lachine 27
Istanbul 26
Lima 25
Santiago 25
Fuzhou 24
Saint Petersburg 24
New York 22
Riverton 22
Athens 20
Berlin 20
Montréal 20
Rochester 20
Trissino 20
Jakarta 18
Saint Louis 18
Xiamen 18
Des Moines 17
Hebei 17
Madrid 17
Harbin 15
Lanzhou 15
Polska 15
Buenos Aires 14
Chicago 14
Redmond 14
Sydney 14
Los Angeles 13
Louisville 13
Osaka 13
Bogotá 12
Mumbai 12
Suzhou 12
Bologna 11
Totale 19038
Nome #
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1102
Diabetic ketoacidosis with SGLT2 inhibitors 1062
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 734
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 651
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 615
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 556
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 549
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 505
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 424
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 340
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 284
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 268
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 240
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 227
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 227
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 207
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 205
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 198
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 186
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 174
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 172
Body fat and C-reactive protein levels in healthy non-obese men. 168
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 165
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 165
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 160
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 155
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 155
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 152
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 152
The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. 150
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 149
Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man 142
Body fat is the main predictor of fibrinogen levels in healthy non-obese men 140
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 138
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 137
Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man 135
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 134
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 134
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 132
Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria 132
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 131
Relationships between human serum resistin, inflammatory markers and insulin resistance 130
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 130
Lipoprotein(a) and insulin treatment in non insulin dependent diabetic patients 129
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 128
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 126
Lipoprotein(a) and insulin treatment in NIDDM patients 126
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 125
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 123
Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. 122
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 122
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 120
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 119
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 119
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 119
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 117
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 117
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 116
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 115
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 114
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 114
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 113
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 113
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 113
Age related changes of glucagon binding and activity in isolated rat hepatocytes. 109
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 109
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 109
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 105
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 104
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 103
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 103
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 103
Nel soggetto normale la ferritemia correla con l’HOMA. 102
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 102
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 99
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 99
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 99
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. 98
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 98
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 97
Plasma Adiponectin Levels in Primary Biliary Cirrhosis: A Novel Perspective for Link Between Hypercholesterolemia and Protection Against Atherosclerosis 96
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 96
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 96
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 95
Metabolic handling of an oral fat load in NAFLD patients. 95
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? 94
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 94
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 94
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 93
Is adiponectin a potential protective factor against atherosclerosis in primary biliary cirrhosis (PBC)? 92
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepadtis (NASH). 92
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 91
Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. 91
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 91
Magnesium and trace element intake after a lifestyle intervention. 89
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up 88
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 88
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 87
Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents 87
Serum free fatty acid composition is associated with different degrees of fibrosis. 86
Totale 18096
Categoria #
all - tutte 47280
article - articoli 0
book - libri 0
conference - conferenze 14836
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62116


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182855 0000 00 0608 1339620165123
2018/20193216 144133256128 163242 156406 159374734321
2019/20205708 218190294527 367867 599388 486495599678
2020/20214922 567326316290 437335 410233 509520391588
2021/20225667 244334279407 388290 464402 3065109561087
2022/20235096 857481197556 5691694 73210 0000
Totale 31631